Acacia Pharma is a British hospital pharmaceutical group which is also active on the American market. The company is focused on the development and commercialization of new nausea & vomiting treatments for surgical and cancer patients.
The admission of Acacia onto Euronext Brussels was the first one in 2018. "The successful IGO of Acacia Pharma is a fine example of Degroof Petercam's internationally renowned expertise in the domain of life sciences. Moreover, the transaction also acknowledges our efforts to put forward Euronext as the reference market for European life sciences companies, including British ones ", François Wohrer, head of Investment Banking at Degroof Petercam, explains.
Please find more information in Acacia Pharma’s press release : http://acaciapharma.com/uploads/default/restricted/Acacia_Pharma_-_Pricing_-_02032018_-_vF.pdf
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT